Evotec Se - American Depositary Shares Each Representing 1/2 Of One Ordinary Share (EVO) closed at $1.52 on October 26, 2026, up 1.3% from the previous close, on volume of 110,826 shares (30-day average 155,454).
Data as of October 26, 2026.
No headlines found.
Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board
PRNewswire (Thu, 15-Oct 2:06 AM ET)
Evotec Announces Chief Scientific Officer Transition
PRNewswire (Tue, 29-Sep 2:05 AM ET)
PRNewswire (Wed, 9-Sep 2:01 AM ET)
PRNewswire (Wed, 2-Sep 2:05 AM ET)
PRNewswire (Thu, 6-Aug 2:18 AM ET)
Business Wire (Mon, 3-Aug 8:32 AM ET)
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
Evotec Se - American Depositary Shares Each Representing 1/2 Of One Ordinary Share trades on the NASDAQ stock market under the symbol EVO.
As of October 27, 2026, EVO stock price climbed to $1.54 with 4,033 million shares trading.
EVO has a beta of 2.96, meaning it tends to be more sensitive to market movements. EVO has a correlation of 0.27 to the broad based SPY ETF.
EVO has a market cap of $547.30 million. This is considered a Small Cap stock.
Last quarter Evotec Se - American Depositary Shares Each Representing 1/2 Of One Ordinary Share reported $167 million in Revenue and -$.15 earnings per share. This fell short of revenue expectation by $-46 million and missed earnings estimates by -$.09.
In the last 3 years, EVO traded as high as $12.00 and as low as $1.33.
EVO has underperformed the market in the last year with a return of -62.4%, while the SPY ETF gained +14.2%. In the last 3 month period, EVO fell short of the market, returning -20.6%, while SPY returned +3.9%. However, in the most recent 2 weeks EVO has outperformed the stock market by returning +12.4%, while SPY returned -1.5%.
EVO support price is $1.46 and resistance is $1.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EVO shares will trade within this expected range on the day.
